Advanced testis cancer

Curr Treat Options Oncol. 2001 Oct;2(5):421-9. doi: 10.1007/s11864-001-0047-z.

Abstract

Advanced testis tumors are highly curable. The treatment strategy is chemotherapy followed by the surgical exeresis of residual disease. The standard chemotherapy regimen is BEP (bleomycin, etoposide, and cisplatin); the number of cycles of chemotherapy depends upon prognostic factors, based on the primary site, histology, presence of visceral metastases, and serum tumor marker levels. Patients in the good-risk group receive three cycles of chemotherapy, whereas those in the intermediate- and high-risk groups receive four cycles. Exeresis of all residual disease and systematic postchemotherapy retroperitoneal dissection in bulky disease are mandatory. When complete exeresis of necrotic tissue, teratoma, or active germ-cell cancer has been performed, no further postsurgical treatment is warranted. A multidisciplinary approach, rigorous administration of chemotherapy, and skill in surgery of germ-cell tumors are favored in the treatment of these patients in trained centers.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood
  • Combined Modality Therapy
  • Epidemiologic Methods
  • Erectile Dysfunction / prevention & control
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis / radiotherapy
  • Male
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Orchiectomy / adverse effects
  • Postoperative Complications / prevention & control
  • Prognosis
  • Radiation Tolerance
  • Retroperitoneal Neoplasms / secondary
  • Retroperitoneal Neoplasms / therapy
  • Risk Factors
  • Salvage Therapy
  • Seminoma / mortality
  • Seminoma / pathology
  • Seminoma / therapy
  • Survival Rate
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / pathology*
  • Testicular Neoplasms / therapy
  • Treatment Outcome

Substances

  • Biomarkers, Tumor